Skip to main content

Saturn Medic

Clinical Cases

Cystic fibrosis (CF)

Clinical Subject Page

Also called

Mucoviscidosis (older term)

ICD-10

E84.9

Specialty

Pulmonology

Onset

Chronic

Reviewed

July 2026
On This Page

Overview

Cystic fibrosis mainly affects the:

  • Lungs
  • Pancreas
  • Gastrointestinal tract
  • Sinuses
  • Reproductive system
  • Sweat glands

Abnormally thick mucus causes airway obstruction, recurrent lung infections, and progressive lung damage.

Etiology & Risk Factors

-Cause:

Cystic fibrosis is caused by mutations in the CFTR gene.

-Inheritance

  • Autosomal recessive
  • Both parents usually carry one abnormal CFTR gene

-Common Mutation

F508del is the most common CFTR mutation.

 

-Risk Factors

  • Family history of cystic fibrosis
  • Sibling with cystic fibrosis
  • Parents who are CFTR mutation carriers

Pathophysiology

CFTR gene mutation
⬇
Abnormal chloride and bicarbonate transport
⬇
Reduced water movement into secretions
⬇
Thick, dehydrated mucus
⬇
Impaired mucus clearance
⬇
Airway obstruction + Bacterial infection
⬇
Chronic inflammation
⬇
Bronchiectasis and progressive lung damage

Other Organs

Thick pancreatic secretions
→ Duct obstruction
→ Pancreatic insufficiency
→ Malabsorption

Abnormal sweat gland function
→ Increased salt loss in sweat

Clinical Presentation

-Respiratory Features

  • Chronic cough

  • Persistent sputum production

  • Recurrent chest infections

  • Wheezing

  • Dyspnea

  • Bronchiectasis

  • Hemoptysis

-Gastrointestinal Features

  • Poor weight gain

  • Malabsorption

  • Steatorrhea

  • Abdominal symptoms

  • Pancreatic insufficiency

-Other Features

  • Salty-tasting skin

  • Chronic sinusitis

  • Nasal polyps

  • Digital clubbing

  • Male infertility

-In Newborns

    • Meconium ileus

    • Failure to thrive

Cystic Fibrosis Overview
Cystic Fibrosis Overview

History Taking

    • Chronic cough?
    • Daily sputum?
    • Recurrent chest infections?
    • Wheezing or dyspnea?
    • Previous bronchiectasis?
    • Poor weight gain?
    • Greasy or bulky stools?
    • Abdominal symptoms?
    • Chronic sinus problems?
    • Nasal polyps?
    • Salty-tasting skin?

Physical Examination

-General Examination

Look for:

  • Low body weight
  • Poor growth
  • Digital clubbing
  • Cyanosis in advanced disease
  • Respiratory distress

-Chest Examination

  • Coarse crackles
  • Wheezing
  • Reduced air entry in advanced disease

-Other Findings

    • Nasal polyps
    • Signs of malnutrition
    • Abdominal distension
    • Signs of chronic liver disease in advanced cases

Investigations

-Sweat Chloride Test — Key Test

Measures the chloride concentration in sweat.

An elevated sweat chloride level supports the diagnosis.

-CFTR Genetic Testing

Used to:

  • Identify CFTR mutations

  • Confirm the diagnosis

  • Determine eligibility for CFTR modulator therapy

-Newborn Screening

May detect cystic fibrosis before symptoms develop.

-Respiratory Tests

  • Sputum culture

  • Pulmonary function tests

  • Chest X-ray

  • CT chest

-Other Tests

    • Pancreatic function testing

    • Nutritional assessment

    • Blood glucose monitoring

    • Liver function tests

Diagnosis

-Diagnosis is based on:

1. Clinical Features or Positive Newborn Screening

Together with:

2. Evidence of CFTR Dysfunction

Demonstrated by:

  • Abnormal sweat chloride testing
  • CF-causing CFTR mutations
  • Specialized CFTR functional testing when needed

Important Note

The sweat chloride test is the main diagnostic test for cystic fibrosis.

Management

Cystic Fibrosis · Treatment

TREATMENT IS MULTIDISCIPLINARY, LIFELONG, AND INCREASINGLY DISEASE-MODIFYING CF is caused by mutations in the CFTR gene → defective chloride channel → thick secretions, recurrent infection, progressive organ damage. Management addresses the underlying CFTR defect (modulators), airway clearance, infection control, nutritional support, and complication prevention.
Core Treatment Pillars
1
CFTR Modulator Therapy
Disease-modifying drugs targeting the underlying CFTR defect — correct protein folding/function, not just symptoms. Transformative when applicable.
Mutation-specific
2
Airway Clearance
Daily physiotherapy techniques (ACBT, PEP, HFCWO) combined with mucolytics to clear thick secretions and reduce infective burden.
Daily — lifelong
3
Infection Management
Prophylactic, suppressive and acute antibiotic therapy targeting chronic colonising organisms (esp. Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia).
Chronic + acute
4
Nutritional & Systemic Support
Pancreatic enzyme replacement, fat-soluble vitamin supplementation, high-calorie diet, CFRD management, and multiorgan complication screening.
Lifelong
Treatment Category Drug / Intervention Notes
CFTR Modulator — Triple Combination Elexacaftor / Tezacaftor / Ivacaftor (ETI, Kaftrio/Trikafta) For F508del (at least one copy, ~90% of patients). Most effective modulator available — dramatic improvement in FEV1, quality of life, and exacerbation rate. Now first-line where eligible.
CFTR Modulator — Potentiator Ivacaftor (Kalydeco) For gating mutations (G551D and others). Opens dysfunctional CFTR channels. Not effective for F508del alone.
CFTR Modulator — Dual Lumacaftor / Ivacaftor (Orkambi) or Tezacaftor / Ivacaftor (Symkevi) For homozygous F508del if ETI not yet available or tolerated. Less effective than ETI.
Mucociliary Clearance Dornase alfa (DNase) inhaled daily — Hypertonic saline 7% inhaled Dornase alfa cleaves extracellular DNA, reducing sputum viscosity. Hypertonic saline hydrates airway surface. Use bronchodilator first, then mucolytic, then physiotherapy.
Chronic Antibiotic Suppression Inhaled tobramycin alternating months — Inhaled aztreonam — Oral azithromycin (3x/week) Targets chronic Pseudomonas colonisation. Azithromycin has anti-inflammatory properties independent of antimicrobial effect. Alternate-month inhaled regimens reduce resistance.
Acute Pulmonary Exacerbation IV antipseudomonal antibiotics (e.g. piperacillin-tazobactam + tobramycin or meropenem) Based on most recent sputum sensitivities. IV for moderate-severe exacerbations; oral for mild. Minimum 14-day course. Intensify airway clearance throughout.
Pancreatic Enzyme Replacement Creon (pancrelipase) with every meal and snack 85% of CF patients have exocrine pancreatic insufficiency. Titrated by stool consistency and fat malabsorption symptoms. Essential for caloric absorption.
Vitamin Supplementation Fat-soluble vitamins A, D, E, K daily Malabsorbed due to pancreatic insufficiency and bile salt abnormalities. Especially important for bone health (vitamin D/K) and infection risk (vitamin A/E).
CF-Related Diabetes (CFRD) Insulin (preferred over oral agents) CFRD affects ~50% of adults. Unique — combined insulin deficiency + resistance. Insulin anabolism also helps maintain weight. Annual OGTT screening from age 10.
Bronchodilators Inhaled SABA (salbutamol) before airway clearance Used to pre-treat before physiotherapy/inhaled therapies; improves tolerance and delivery of subsequent treatments.
Lung Transplantation Bilateral lung transplant Definitive treatment for end-stage CF lung disease. Consider referral when FEV1 <30% predicted or rapid decline. Does not cure systemic CF manifestations.
Complications to Monitor
CF-related diabetes (CFRD) — annual OGTT from age 10; insulin is treatment of choice
CF-related bone disease — DEXA scanning; vitamin D + bisphosphonates if indicated
CF liver disease — cirrhosis/portal hypertension in ~10%; ursodeoxycholic acid; consider transplant
Haemoptysis — minor is common; massive haemoptysis requires bronchial artery embolisation
Pneumothorax — increased risk; treat as standard but avoid vigorous physiotherapy acutely
Infertility — males almost universally infertile (CBAVD); females reduced fertility; offer counselling
Routine Monitoring
Spirometry — every clinic visit; FEV1 is primary marker of disease progression
Sputum MC&S — every clinic visit; guides antibiotic selection for exacerbations
Weight/BMI/nutritional assessment — every visit; target BMI ≥22 (female) or ≥23 (male)
Annual OGTT — from age 10 for CFRD screening
Annual blood tests — LFTs, vitamin levels (A/D/E), HbA1c, renal function (if aminoglycosides used)
DEXA scan — every 2–5 years from adulthood; more frequent if bone disease present

Complications

  • Bronchiectasis
  • Recurrent pulmonary infections
  • Respiratory failure
  • Hemoptysis
  • Pneumothorax
  • Pancreatic insufficiency
  • Malnutrition
  • Cystic fibrosis-related diabetes
  • Liver disease
  • Osteoporosis
  • Infertility
  • Death

Prognosis

  • Cystic fibrosis is a chronic progressive disease, but survival has improved greatly with modern treatment.
  • Prognosis depends mainly on:
    • Severity of lung disease
    • CFTR mutation
    • Frequency of pulmonary exacerbations
    • Nutritional status
    • Presence of complications
  • Early diagnosis and specialized multidisciplinary care improve outcomes.
  • CFTR modulator therapy has significantly improved outcomes for many eligible patients.

Key Points / Clinical Pearls

  • Cystic fibrosis is an autosomal recessive disease caused by CFTR mutations.
  • Thick secretions affect multiple organs, especially the lungs and pancreas.
  • Chronic cough and recurrent respiratory infections are common.
  • Pancreatic insufficiency causes malabsorption and poor growth.
  • The sweat chloride test is the key diagnostic test.
  • Respiratory cultures guide antibiotic therapy.
  • Airway clearance is a cornerstone of treatment.
  • Pancreatic enzymes and nutritional support are essential in pancreatic insufficiency.
Test yourself

Practice Cystic fibrosis (CF) questions

Lock in what you just read with exam-style MCQs and active-recall flashcards from Saturn Medic.